DALLAS & MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--Aug 17, 2026--
Concentra® (NYSE: CON), the nation's leader in occupational and workforce health services, today announced completion of its acquisition of four Minnesota Occupational Health (MOH) medical centers in the Twin Cities. The acquisition strengthens access to specialized occupational health care for Minnesota employees and connects experienced local care teams with Concentra’s national clinical and operational resources.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817392661/en/
Beginning August 17, the medical centers will operate as Concentra, providing continuity of care for existing patients and employer customers while integrating the company’s clinical standards, technology and specialized occupational health expertise. Concentra also plans to invest in enhancing the care experience across the centers, including significant improvements to its St. Paul/Midway center that will establish it as a flagship occupational health center for the region.
“Employees across Minnesota deserve access to trusted occupational health care that understands their needs and provides reliable support when and where it matters,” said Mike Kosuth, executive vice president and chief operating officer, East Group, Concentra. “By welcoming experienced local teams into Concentra’s connected network, we can expand access to specialized occupational health expertise and deliver a consistent care experience for employees across the region.”
Concentra has served Minnesotans since 2018. With this acquisition, Concentra will operate eight medical centers across the state, making it easier for workers to access timely care and employers to manage workforce health across multiple locations through a consistent clinical and operational model. The acquired centers are located at:
“Access to quality occupational health care is an important part of supporting a strong and resilient workforce,” said Mike Logan, president and CEO, MPLS Regional Chamber. “Concentra’s expanded presence in the Twin Cities gives local employers and employees greater access to specialized services that can help keep people healthy, safe, and productive. Continued investment in workforce health is good for our businesses, our employees, and the economic vitality of communities across the region.”
Concentra provides a full range of occupational health services, including work injury care, physical therapy, drug testing, Department of Transportation physical exams, pre-placement exams, medical surveillance services, and workforce health programs focused on injury prevention, employee well-being, workforce readiness, and the acceleration of safe return-to-work outcomes. Telemedicine for minor work injuries will also be available through Concentra Telemed®, the company's proprietary telemedicine platform.
Patients and employers can find center hours, services and more information at www.concentra.com.
About Concentra
Concentra is the largest provider of occupational health services in the United States by number of locations, with the mission of improving the health of America’s workforce, one patient at a time. Our approximately 13,000 colleagues and affiliated physicians and clinicians support the delivery of an extensive suite of services, including occupational and consumer health services and other direct-to-employer care. We support the care of approximately 54,000 patients each business day on average across 46 states and the District of Columbia at our 633 occupational health centers, 415 onsite health clinics at employer worksites, and Concentra Telemed as of June 30, 2026.
Concentra Strengthens Workforce Health Access in Minnesota Through Acquisition
NEW YORK--(BUSINESS WIRE)--Aug 17, 2026--
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) and reminds investors of the August 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817839374/en/
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Embecta knew or recklessly disregarded that the Company's guidance was misleading and unattainable. In fact, Embecta touted the Company's pen needle business as "incredibly resolute" mere weeks prior to missing expectations and cutting 2026 fiscal guidance.
On May 5, 2026, Embecta published second quarter 2026 fiscal results disclosing that the Company failed to meet its guidance for second quarter 2026 and lowered fiscal year 2026 guidance. In particular, Embecta revealed that revenue declined over 14%, much higher than the guidance of flat to a decline of 2% and that the Company was lowering estimates on US performance, largely in part due to weakness in its pen needle sales.
Following this news, the price of Embecta's common stock declined dramatically. From a closing market price of $9.25 per share on May 4, 2026, Embecta's stock price fell to $3.90 per share on May 5, 2026, a decline of over 57.8% in a single day.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Embecta’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Embecta class action, go to www.faruqilaw.com/EMBC or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Embecta Securities Class Action Lawsuit:
What is the Embecta securities fraud lawsuit about?
Faruqi & Faruqi, LLP has filed a securities class action lawsuit alleging that Embecta Corp. (NASDAQ: EMBC) and certain of its officers and directors made materially false and misleading statements to investors during the Class Period. The lawsuit alleges that defendants concealed adverse facts concerning the true state of Embecta's financial results and that the Company's publicly issued guidance was misleading and allegedly unattainable. Specifically, the complaint alleges that Embecta touted its pen needle business as "incredibly resolute" just weeks before the Company missed its own guidance and was forced to cut its fiscal year 2026 outlook. On May 5, 2026, Embecta disclosed second quarter 2026 results showing a revenue decline of over 14% — far exceeding the guided range of flat to a decline of 2% — largely attributed to weakness in pen needle sales, causing the Company's stock price to fall approximately 57.8% in a single trading session. The lawsuit alleges that these circumstances caused investors to purchase Embecta securities at artificially inflated prices.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Embecta Corp. (NASDAQ: EMBC) securities on the NASDAQ between November 25, 2025 and May 4, 2026, inclusive, may be eligible to participate in this class action lawsuit. The lawsuit is brought on behalf of all such investors who allegedly suffered losses as a result of the conduct described in the complaint. Eligibility to participate in any potential recovery is not limited to those who seek appointment as lead plaintiff; all class members who purchased during the Class Period may be entitled to share in any recovery ultimately obtained. Investors who believe they may be eligible are encouraged to review their trading records for transactions in Embecta securities during the Class Period.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative who leads the litigation on behalf of the entire class of similarly situated investors and works with counsel to make key decisions regarding the prosecution of the case. Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Embecta securities during the Class Period may move the court to serve as lead plaintiff, and the court generally appoints the movant with the largest financial interest in the litigation who also satisfies applicable legal requirements. The deadline to file a motion for appointment as lead plaintiff is the lead plaintiff deadline applicable to this case, and investors wishing to seek this role should take action before that date. Importantly, investors do not need to serve as lead plaintiff in order to share in any recovery — class membership and potential recovery are available to all eligible investors regardless of whether they seek a leadership role in the litigation.
What should investors do if they purchased Embecta stock during the Class Period?
Investors who purchased Embecta Corp. (NASDAQ: EMBC) securities between November 25, 2025 and May 4, 2026, inclusive, are encouraged to promptly review their brokerage and trading records to confirm any purchases made during the Class Period. It is important to preserve all documentation related to those transactions, including trade confirmations, account statements, and any communications concerning Embecta securities, as such records may be relevant to establishing eligibility and assessing losses. Investors should evaluate their legal options in light of the pending lead plaintiff deadline, as certain procedural rights are time-sensitive. Faruqi & Faruqi, LLP is available to speak with investors, review their potential claims, and answer questions about the litigation process prior to the applicable deadline, with no obligation to serve as lead plaintiff in order to participate in any recovery.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Embecta securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
